ViewRay (NASDAQ: VRAY) and Thermo Fisher Scientific (NYSE:TMO) are both advanced medical equipment & technology – nec companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for ViewRay and Thermo Fisher Scientific, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ViewRay 0 0 5 0 3.00
Thermo Fisher Scientific 0 1 14 0 2.93

ViewRay presently has a consensus price target of $10.60, indicating a potential upside of 12.41%. Thermo Fisher Scientific has a consensus price target of $205.00, indicating a potential upside of 7.55%. Given ViewRay’s stronger consensus rating and higher probable upside, research analysts plainly believe ViewRay is more favorable than Thermo Fisher Scientific.


Thermo Fisher Scientific pays an annual dividend of $0.60 per share and has a dividend yield of 0.3%. ViewRay does not pay a dividend. Thermo Fisher Scientific pays out 10.2% of its earnings in the form of a dividend.

Earnings & Valuation

This table compares ViewRay and Thermo Fisher Scientific’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
ViewRay $22.24 million 28.60 -$50.63 million ($1.09) -8.65
Thermo Fisher Scientific $18.27 billion 4.18 $2.02 billion $5.89 32.36

Thermo Fisher Scientific has higher revenue and earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.


This table compares ViewRay and Thermo Fisher Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ViewRay -193.53% N/A -60.50%
Thermo Fisher Scientific 11.73% 15.94% 7.41%

Institutional & Insider Ownership

53.9% of ViewRay shares are held by institutional investors. Comparatively, 83.8% of Thermo Fisher Scientific shares are held by institutional investors. 62.8% of ViewRay shares are held by company insiders. Comparatively, 0.5% of Thermo Fisher Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


Thermo Fisher Scientific beats ViewRay on 9 of the 14 factors compared between the two stocks.

About ViewRay

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables. The Analytical Instruments segment provides a range of instruments, consumables, software and services. The Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers controlled temperature technologies products, growth protection and separation products, and water and laboratory products.

Receive News & Stock Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related stocks with our FREE daily email newsletter.